All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F16%3AN0000078" target="_blank" >RIV/00064190:_____/16:N0000078 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/16:10323354 RIV/00216208:11150/16:10323354

  • Result on the web

    <a href="http://dx.doi.org/10.4149/313_150913N485" target="_blank" >http://dx.doi.org/10.4149/313_150913N485</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.4149/313_150913N485" target="_blank" >10.4149/313_150913N485</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The prognostic significance of epidermal growth factor receptor expression in patients with anal carcinoma

  • Original language description

    The aim of the present retrospective study was to evaluate the prognostic significance of epidermal growth factor receptor (EGFR) expression in patients treated with radiotherapy or concomitant chemoradiotherapy for squamous cell anal cancer (SCAC) Patients and methods: A total of 17 patients with SCAC (clinical stages I-III) were studies. All patients were treated with radiotherapy (total dose range 40 68 Gy), 13 patients received concomitant chemotherapy (7 patients mitomycin/5-fluorouracil, 5 patients cisplatine/5-fluorouracil, 1 patient cisplatine weekly). EGFR expression in the pretreatment biopsieswas assessed with imunohistochemistry. Patients with EGFR expression had significantly shorter progression free survival (PFS) (p=0.0109; HR 9.38, 95% CI 1.75 - 50.35) and overall survival (OS) (p=0.0351; HR 7.11, 95% CI 1.4 - 36.13) than patients without expression EGFR. The 4-year PFS in patients with increased EGFR expression was only 28.57% (95% CI 17.07 - 62.04%) compared to 87.5% (95% CI 64.58 - 100%) in patients without EGFR expression. The 4-year OS in patients with increased EGFR expression was only 50.0% (95% CI 15.35 - 84.65%) compared to 87.5% (95% CI 64.58 - 100.0%) in patients without EGFR expression. Patients with expression EGFR had significantly shorter PFS and OS compared with patients without EGFR expression.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    NEOPLASMA

  • ISSN

    0028-2685

  • e-ISSN

  • Volume of the periodical

    63

  • Issue of the periodical within the volume

    3

  • Country of publishing house

    SK - SLOVAKIA

  • Number of pages

    6

  • Pages from-to

    435-441

  • UT code for WoS article

    000377058000013

  • EID of the result in the Scopus database

    2-s2.0-84969670585